SCHEMBL5367281

SCHEMBL5367281

O=S(=O)(c1ccc(N2CCN(c3ccc(O)cc3)CC2)c2nonc12)N1CCN(c2ccc(O)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
MAPT P10636 6/20 0.53
ALDH1A1 P00352 6/20 0.53
LMNA P02545 4/20 0.47
POLB P06746 2/20 0.47
PKM P14618 1/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
GAA P10253 4/20 0.46
JAK2 O60674 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
GFER P55789 1/20 0.45
THRB P10828 2/20 0.44
CHRM1 P11229 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5371333 0.88 MEN1 (0.54) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL5244389 0.88 MEN1 (0.56) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL8153263 0.84 MAPT (0.51) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL5292057 0.78 MEN1 (0.47) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL5243664 0.75 ALDH1A1 (0.61) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL5341701 0.74 MEN1 (0.68) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL5243045 0.72 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL5284517 0.71 HSD11B1 (0.62)
SCHEMBL2962551 0.70 KMT2A (0.80) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL5243352 0.70 KMT2A (0.43) MEN1KMT2AMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP MEN1 3562/4885KMT2A 1303/4885MAPT 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.